A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.
Actinic Keratoses
DRUG: PEP005 (ingenol mebutate) Gel|DRUG: Vehicle gel
Patients With Complete Clearance of Actinic Keratosis (AKs), Complete clearance rate of actinic keratosis (AK) lesions defined as the proportion of patients with no clinically visible AK lesions in the selected treatment area., 57 days
Patients With Partial Clearance of Actinic Keratosis (AKs), Partial clearance rate of AK lesions defined as the proportion of patients with a 75% or greater reduction in the number of actinic keratosis (AK) lesions identified at baseline in the selected treatment area., baseline and 57 days
The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.